NCT00580684

Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children

Long-Term Efficacy of Pneumococcal Conjugate 7-Valent Vaccine Versus Plain Polisaccharide Pneumococcus Vacine in Reducing Pneumococcal Nasopharyngeal Carriage of Children.

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 101 (actual)
• Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 2 Years – 9 Years
• Healthy volunteers: Accepted

Summary

To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization. To evaluate the rate of penicillin-resistant pneumococci in nasopharyngeal carriage.

Detailed description

This study will require 6 months to be completed (3 months for nasopharyngeal samples collection; 3 months dor analysis). Each child will participate for a 1 day period.

Conditions

• Vaccines, Pneumococcal
• Vaccines, Pneumococcal Conjugate Vaccine

Interventions

Type	Name	Description
BIOLOGICAL	pneumococcus conjugate vaccine 7 valent to reduce carriage	plain polisacaride vaccine 23 valent to reduce carriage

Timeline

• Start date: 2003-09-01
• Completion: 2004-08-01
• First posted: 2007-12-27
• Last updated: 2007-12-27